<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00715429</url>
  </required_header>
  <id_info>
    <org_study_id>H-2007-0255</org_study_id>
    <nct_id>NCT00715429</nct_id>
  </id_info>
  <brief_title>Vitamin D for Painful Nocturnal Leg Cramps</brief_title>
  <official_title>Nocturnal Leg Cramps in the Elderly: Randomized Controlled Trial of Ergocalciferol (Vitamin D2) for a Painful and Distressing Problem</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mayday Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Research question: Does vitamin D reduce the frequency and severity of nocturnal leg
           cramps in older persons who previously took quinine for leg cramps?

        2. Experimental Design: This is a randomized, double blind, placebo controlled study of 70
           men and women veterans receiving care at the Madison VA Medical Center(VAMC) or at the
           University of Wisconsin Hospitals and Clinics (UWHC). Individuals age 50 or more who
           have previously taken quinine for nocturnal leg cramps and meeting baseline criteria are
           eligible to enroll. Enrollees meeting laboratory criteria, including low-normal vitamin
           D levels, will undergo a 2-week &quot;diary run-in&quot; period to confirm cramp frequency. Those
           who report two or more leg cramps in each week will continue in the study and will be
           randomized to vitamin D or placebo. After a two-week wash-in, subjects will take a
           vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly
           vitamin D (50,000 units) maintenance dose for 7 weeks. Subjects will record by diary the
           number and severity of leg cramps from the start of the &quot;diary run-in&quot; until a week
           after the last dose of study drug. Study investigators will call subjects at scheduled
           intervals to assess compliance, tolerability, and diary use.

        3. Major risks to subjects: No major risks are anticipated. Excessive vitamin D can
           increase blood calcium levels (hypercalcemia), with symptoms such as thirst, nausea, and
           weakness. However, symptomatic hypercalcemia has not been reported except for those
           taking more than 40,000 units daily for several months. This is far above the cumulative
           dose in our study.

        4. Potential benefits: Subjects may not receive any benefit. Vitamin D may alleviate leg
           cramps for subjects who receive it.

        5. Consent Procedure: Flyers describing the study and telephone contact information will be
           mailed to patients who have received quinine during the period 2002-2007. The PI or
           Co-PI will return calls to describe the study and answer any questions. For persons
           meeting preliminary (pre-lab) study criteria, two copies of the consent form will be
           mailed, with the patient mailing back one signed consent to the PI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled trial to determine if oral vitamin D
      administration reduces the number or severity of nocturnal leg cramps, compared to placebo.
      Symptom diaries will be used throughout the study to assess frequency and severity of cramps.
      We will enroll a total of 70 men and women at least 50 years of age who have nocturnal leg
      cramps at least twice weekly and have previously received quinine for this. Those meeting
      baseline laboratory criteria and who report at least two leg cramps per week in a two-week
      &quot;diary run-in&quot; period will be randomized to vitamin D or placebo. Baseline, mid-study, and
      final laboratory testing will assess any changes in 25-hydroxyvitamin D(OHD) and related
      variables (25-hydroxyvitamin D is the best measure of vitamin D status.) The time from the
      beginning of the diary run-in through the final dose of drug and last labs,will be about 14
      weeks.

      Optimal vitamin D status for health is unknown, although many experts aim for serum
      25-hydroxyvitamin D of 35-40 ng/ml. Subjects in this study randomized to vitamin D will take
      a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin
      D (50,000 units) maintenance dose for 7 weeks. Based on published literature on the ability
      of vitamin D to raise serum 25-OHD over time, we estimate that the loading doses will &quot;boost&quot;
      levels after 10 days by an increment of ~40ng/ml (up to ~65 ng/mL total, starting with a
      typical person's baseline of 25ng/ml). This achieved level of 65 is within the reference
      range of our VA's reference range of 20-100. (In the PI's experience, most veterans without
      special D supplementation have baseline levels between 15 and 40).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We exhausted potential candidates before reaching goal of 70; recruited 29, 13 completed the
    study
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Nocturnal Leg Cramp Rate</measure>
    <time_frame>baseline and 77 day</time_frame>
    <description>Difference in number of leg cramps per day during treatment period compared to baseline period.
Participants will undergo a 2-week &quot;diary run-in&quot; period to confirm cramp frequency. After a 2 week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks. Subjects will record by diary the number and severity of leg cramps from the start of the &quot;diary run-in&quot; until 1 week after the last dose of study drug/placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Calcium Level</measure>
    <time_frame>Day 77</time_frame>
    <description>Serum calcium was measured to detect any possible correlation between high dose of Vitamin D and hypercalcemia. Hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Leg Cramps, Nocturnal</condition>
  <arm_group>
    <arm_group_label>vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo x 10d, + placebo weekly 7 wks</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin d</intervention_name>
    <description>After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.</description>
    <arm_group_label>vitamin D 50,000 U/d x 10d, + vitamin D 50,000 U weekly 7 wks</arm_group_label>
    <other_name>ergocalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.</description>
    <arm_group_label>placebo x 10d, + placebo weekly 7 wks</arm_group_label>
    <other_name>lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  One or more prescription for quinine at the Madison VA in the last 5 years, or else be
             a UWHC (U Wisconsin Health Clinics) patient whose UWHC medication list had quinine
             listed in the last five years

          -  At least 50 years of age, with women being past menopause. This is defined as the
             woman reporting no periods in the last 12 consecutive months or longer.

          -  Leg cramps listed in medical record,

          -  Ability &amp; willingness to give informed consent,

          -  Stable estimated Glomerular filtration rate (GFR)&gt;35 ml/min for the prior 6 mos,

          -  No change in diuretic therapy in last 3 months,

          -  Stable pattern of two or more cramps per week for past three months,

          -  Ability to complete daily diary entry,

          -  Post-consent: serum 25-OH of 20-45 ng/mL, albumin- corrected calcium &lt;10.3 mg/dL, and
             urine calcium/creatinine ratio &lt;0.25.

        Exclusion Criteria:

          -  Not receiving primary care at Madison VAMC, or at UWHC

          -  Hyperparathyroidism (1°, 2°, or 3°),

          -  Osteomalacia ,

          -  Paget's disease,

          -  Metastatic cancer,

          -  Taking vitamin D 50,000 units capsules,

          -  Serum Ca++ &gt;10.3 mg/dL in subject chart,

          -  Sarcoidosis or tuberculosis, and

          -  Peripheral vascular disease or other condition confounding assessment of cramps.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary E Elliott, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 10, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2008</study_first_posted>
  <results_first_submitted>December 11, 2013</results_first_submitted>
  <results_first_submitted_qc>August 26, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2019</results_first_posted>
  <last_update_submitted>August 26, 2019</last_update_submitted>
  <last_update_submitted_qc>August 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leg cramps</keyword>
  <keyword>vitamin D deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Sleep-Wake Transition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>15 participants got excluded from the study due to not fulfilling the inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D 50,000 U/d x 10d, + Vitamin D 50,000 U Weekly 7 Wks</title>
          <description>Vitamin D arm
vitamin d: After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo x 10d, + Placebo Weekly 7 Wks</title>
          <description>placebo
placebo: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not complete the study diary</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D 50,000 U/d x 10d, + Vitamin D 50,000 U Weekly 7 Wks</title>
          <description>Vitamin D arm
vitamin d: After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo x 10d, + Placebo Weekly 7 Wks</title>
          <description>placebo
placebo: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78" lower_limit="64" upper_limit="87"/>
                    <measurement group_id="B2" value="73" lower_limit="62" upper_limit="79"/>
                    <measurement group_id="B3" value="76" lower_limit="62" upper_limit="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leg cramp frequency mean over 2 week prestudy</title>
          <description>Eligibility requirements included having at least two cramps weekly.</description>
          <units>cramps/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.74" spread="0.56"/>
                    <measurement group_id="B2" value="1.27" spread="1.15"/>
                    <measurement group_id="B3" value="1.005" spread="0.855"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>25-hydroxyvitamin D concentration</title>
          <description>Eligibility requirements included having 25-hydroxyvitamin D concentration between 20 and 45 ng/ml.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" spread="6"/>
                    <measurement group_id="B2" value="34" spread="8"/>
                    <measurement group_id="B3" value="37" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum calcium</title>
          <description>Eligibility requirements included having normal serum calcium ranging from 8.5-10.2 mg/dL.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" spread="0.2"/>
                    <measurement group_id="B2" value="9.1" spread="0.4"/>
                    <measurement group_id="B3" value="9.05" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine calcium /creatinine ratio</title>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.09" spread="0.10"/>
                    <measurement group_id="B2" value="0.10" spread="0.08"/>
                    <measurement group_id="B3" value=".095" spread=".09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Estimated Glomerular Filtration Rate (eGFR)</title>
          <units>ml/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="19.6"/>
                    <measurement group_id="B2" value="81" spread="25"/>
                    <measurement group_id="B3" value="75" spread="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Nocturnal Leg Cramp Rate</title>
        <description>Difference in number of leg cramps per day during treatment period compared to baseline period.
Participants will undergo a 2-week &quot;diary run-in&quot; period to confirm cramp frequency. After a 2 week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks. Subjects will record by diary the number and severity of leg cramps from the start of the &quot;diary run-in&quot; until 1 week after the last dose of study drug/placebo.</description>
        <time_frame>baseline and 77 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D
vitamin d: After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
placebo: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Nocturnal Leg Cramp Rate</title>
          <description>Difference in number of leg cramps per day during treatment period compared to baseline period.
Participants will undergo a 2-week &quot;diary run-in&quot; period to confirm cramp frequency. After a 2 week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks. Subjects will record by diary the number and severity of leg cramps from the start of the &quot;diary run-in&quot; until 1 week after the last dose of study drug/placebo.</description>
          <units>cramps/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.28"/>
                    <measurement group_id="O2" value="-0.05" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.27</p_value>
            <p_value_desc>Daily cramp rate at baseline&amp; on treatment, were calculated as % of each subjects total # of cramps, for comparison among subjects. Change in % cramp rates from baseline to treatment was computed for each subject in vit D and placebo groups.</p_value_desc>
            <method>t-test, 2 sided</method>
            <method_desc>T test was used to compare the change in % cramp rate from baseline to treatment for each subject in each treatment group.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Calcium Level</title>
        <description>Serum calcium was measured to detect any possible correlation between high dose of Vitamin D and hypercalcemia. Hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL.</description>
        <time_frame>Day 77</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D</title>
            <description>Vitamin D
vitamin d: After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
placebo: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Calcium Level</title>
          <description>Serum calcium was measured to detect any possible correlation between high dose of Vitamin D and hypercalcemia. Hypercalcemia is defined as a serum calcium level greater than 10.5 mg/dL.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="0.3"/>
                    <measurement group_id="O2" value="9.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D 50,000 U/d x 10d, + Vitamin D 50,000 U Weekly 7 Wks</title>
          <description>Vitamin D arm
vitamin d: After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo x 10d, + Placebo Weekly 7 Wks</title>
          <description>placebo
placebo: After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <description>long term undiagnosed anemia, sees hematology clinic</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>diabetic patient took too much insulin, dose was lowered</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastroesophageal reflux</sub_title>
                <description>patient given Prilosec for this</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>musculoskeletal pain</sub_title>
                <description>arthritis pain, periodic</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>post traumatic stress disorder</sub_title>
                <description>temporary worsening of long standing ptsd from Vietnam experience</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>rise in PSA</sub_title>
                <description>patient had history of prostate cancer</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The enrollment was very small</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mary Elliott</name_or_title>
      <organization>University of Wisconsin School of Pharmacy</organization>
      <phone>608-695-7501</phone>
      <email>meelliott@pharmacy.wisc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

